PARM PTO-1449 (Modified)
Approved for use through 10/31/2002

US DEPARTMENT OF COMMERCE Docket No.

US Patent and Trademark Office INFORMATION DISCLOSURE CITATION

Application No. 10/815,421

Applicant

50623.00359

Syed F.A. Hossainy

Filing Date March 31, 2004 Group Art Unit 1614

(Use several sheets if necessary)

in an Application

			U.S. PAT	ENT DOCUMENTS			
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
Ca.	A1	2,072,303	3/2/37	Herrmann et al.	128	335.5	10/14/33
Î	A2	2,386,454	10/9/45	Frosch et al.	260	78	11/22/40
	А3	3,773,737	11/20/73	Goodman et al.	260	78	6/9/71
•	A4	3,849,514	. 11/19/74	Gray, Jr. et al.	260	857	9/5/69
	A5	4,226,243	10/7/80	Shalaby et al.	128	335.5	7/27/79
1	A6	4,329,383	5/11/82	Joh	428	36	7/21/80
	A7	4,343,931	8/10/82	Barrows	528	291	12/17/79
	A8	4,529,792	7/16/85	Barrows	528	291	5/6/82
	A9	4,611,051	9/9/86	Hayes et al.	528	295.3	12/31/85
	A10	4,656,242	4/7/87	Swan et al.	528	295.3	6/7/85
	A11	4,733,665	3/29/88	Palmaz	128	343	11/7/85
	A12	4,800,882	1/31/89	Gianturco	128	343	3/13/87
·	A13	4,882,168	11/21/89	Casey et al.	424	468	9/5/86
	A14	4,886,062	12/12/89	Wiktor	128	343	10/19/87
	A15	4,931,287	6/5/90	. Bae et al.	424	484	6/14/88
	A16	4,941,870	7/17/90	Okada et al.	600	36	12/30/88
	A17	4,977,901	12/18/90	Ofstead	128	772	4/6/90
	A18	5,019,096	5/28/91	Fox, Jr. et al.	623	1	10/14/88
.	A19	5,100,992	3/31/92	Cohn et al.	424	501	5/3/90
	A20	5,112,457	5/12/92	Marchant	204	165	7/23/90
	A21	5,133,742	7/28/92	Pinchuk	623	1	. 11/14/91
	A22	5,163,952	11/17/92	Froix	623	1	9/14/90
	A23	5,165,919	11/24/92	Sasaki et al.	424	488	9/26/90
1/	A24	5,219,980	6/15/93	Swidler	528	272	4/16/92
W	A25	5,258,020	11/2/93	Froix	623	1	4/24/92
OS)	A26	5,272,012	12/21/93	Opolski	428	423.1	1/29/92

		•		·			
	A27	5,292,516	3/8/94	Viegas et al.	424	423	11/8/91
T	A28	5,298,260	3/29/94	Viegas et al.	424	486	6/9/92
1	A29	5,300,295	4/5/94	Viegas et al.	424	427	9/13/91
	A30	5,306,501	4/26/94	Viegas et al.	424	423	11/8/91
	A31	5,306,786	4/26/94	Moens et al.	525	437	12/16/91
	A32	5,328,471	7/12/94	Slepian	604	101	8/4/93
	A33	5,330,768	7/19/94	Park et al.	424	501	7/5/91
	A34	5,380,299	1/10/95	Fearnot et al.	604	265	8/30/93
	A35	5,417,981	5/23/95	Endo et al.	424	486	4/28/93
	A36	5,447,724	9/5/95	Helmus et al.	424	426	11/15/93
	A37	5,455,040	10/3/95	Marchant	424	426	11/19/92
	A38	5,462,990	10/31/95	Hubbell et al.	. 525	54.1	10/5/93
	- A39	5,464,650	11/7/95	Berg et al.	427	2.30	4/26/93
	A40	5,485,496	1/16/96	Lee et al.	378	64	9/22/94
	A41	5,516,881	5/14/96	Lee et al.	528	320	8/10/94
	A42	5,569,463	10/29/96	Helmus et al.	424	426	6/7/95
	A43	5,578,073	11/26/96	Haimovich et al.	623	1	9/16/94
•	A44	5,584,877	12/17/96	Miyake et al.	623	1	6/23/94
	A45	5,605,696	2/25/97	Eury et al.	424	423	3/30/95
	A46	5,607,467	3/4/97	Froix	623	1	6/23/93
	.A47	5,609,629	3/11/97	Fearnot et al.	623	1	6/7/95
	A48	5,610,241	3/11/97	Lee et al.	525	411	5/7/96
	A49	5,616,338	4/1/97	Fox, Jr. et al.	424	423	4/19/91
	A50	5,624,411	4/29/97	Tuch .	604	265	6/7/95
	A51	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
	A52	5,644,020	7/1/97	Timmermann et al.	528	288	5/10/96
	A53	5,649,977	7/22/97	Campbell	623	1	9/22/94
	A54	5,658,995	8/19/97	Kohn et al.	525	432	11/27/95
	A55	5,667,767	9/16/97	Greff et al.	424	9.411	7 <i>/</i> 27/95
	A56	5,670,558	9/23/97	Onishi et al.	523	112	7/6/95
A	A57	5,674,242	10/7/97	Phan et al.	606	198	11/15/96
	A58	5,679,400	10/21/97	Tuch '·	427	2.14	6/7/95
18	A59	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96

-6	7 7			-	407	2.42	2/22/05
CEO /	A60	5,702,754	12/30/97	Zhong	427	2.12	2/22/95
	A61	5,711,958	1/27/98	Cohn et al.	424	423	7/11/96
	A62	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
	A63	5,721,131	2/24/98	Rudolph et al.	435	240	4/28/94
	A64	5,723,219	3/3/98	Kolluri et al.	428	411.1	12/19/95
	A65	5,735,897	4/7/98	Buirge	623	12	1/2/97
	A66	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
	A67	5,759,205	6/2/98	· Valentini	623	16	1/20/95
	A68	5,776,184	7/7/98	Tuch	623	1	10/9/96
	A69	5,783,657	7/21/98	Pavlin et al.	528	310	10/18/96
	A70	5,788,979	8/4/98	Alt et al.	424	426	2/10/97
	A71	5,800,392	9/1/98	Racchini	604	96	5/8/96
	A72	5,820,917	10/13/98	Tuch	427	2.1	6/7/95
	A73	5,824,048	10/20/98	· Tuch	623	1	10/9/96
	A74	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
	A75	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
	A76	5,837,008	11/17/98	Berg et al.	623	1	4/27/95
	A77	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
	A78	5,849,859	12/15/98	Acemoglu	528	271	3/23/93
	A79	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97
	A80	5,854,376	12/29/98	Higashi	528	288	3/11/96
	A81	5,858,746	1/12/99	Hubbell et al.	435	177	1/25/95
	A82	5,865,814	2/2/99	Tuch	604	265	8/6/97
	A83	5,869,127	2/9/99	Zhong	427	2.12	6/18/97
	A84	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97
	A85	5,876,433	3/2/99	Lunn	623	1	5/29/96
	A86	5,877,224	3/2/99	Brocchini et al.	514	772.2	7/28/95
	A87	5,879,713	3/9/99	Roth et al.	424	489	1/23/97
	A88	5,902,875	5/11/99	Roby et al.	528	310	1/28/98
	A89	5,905,168	5/18/99	Dos Santos et al.	562	590	12/10/93
	A90	5,910,564	6/8/99	Gruning et al.	528	310	12/6/96
	A91	5,914,387	6/22/99	Roby et al.	528	310	1/28/98
(4)	A92	5,919,893	7/6/99	Roby et al.	525	411	1/28/98

(0)	A93	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
	A94	5,932,299	8/3/99	Katoot	427	508	4/22/97
	A95	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
	A96	5,958,385	9/28/99	Tondeur et al.	424	61	9/28/95
	A97	5,962,138	10/5/99	Kolluri et al.	428	411.1	11/24/97
	A98	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
			11/9/99	Terry	424	427	7/29/97
	A99	5,980,928			427	2.24	9/22/97
	A100	5,980,972	11/9/99	Ding			
	A101	5,997,517	12/7/99	Whitbourne	604	265	1/27/97
•	A102	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A103	6,011,125	1/4/00	Lohmeijer et al.	525	440	9/25/98
	A104	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A105	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
	A106	6,034,204	3/7/00	Mohr et al.	528	328	8/7/98
	A107	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
•	A108	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A109	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
	A110	6,054,553	4/25/00	Groth et al.	528	335	11/12/96
	A111	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A112	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A113	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A114	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
	A115	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A116	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A117	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A118	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A119	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A120	6,120,491	9/19/00	Kohn et al.	604	502	4/7/98
	A121	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A122	6,120,788	9/19/00	Barrows	424	426	10/16/98
	A123	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A124	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
50%	A125	6,129,761	10/10/00	Hubbell	623	11	6/7/95

		<u></u>					
42	- A126	6,136,333	10/24/00	Cohn et al.	424	423	7/11/97
\mathcal{I}	A127	6,143,354	11/7/00	Koulik et al.	. 427	2.24	2/8/99
	A128	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A129	6,159,978	12/12/00	Myers et al.	514	252.1	11/24/98
	A130	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
	A131	6,172,167	1/9/01	Stapert et al.	525	420	6/27/97
	A132	6,177,523	1/23/01	Reich et al.	525	459	7/14/99
	A133	6,180,632	. 1/30/01	Myers et al.	.514	252.1	11/24/98
	A134	6,203,551	3/20/01	Wu	606	108	10/4/99
٠	A135	6,211,249	4/3/01	Cohn et al.	514	772.1	1/13/98
	A136	6,214,901	4/10/01	Chudzik et al.	523	113	4/15/99
	A137	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	A138	6,240,616	6/5/01	Yan	29	527.2	4/15/97
	A139	6,245,753	6/12/01	Byun et al.	. 514	56	4/27/99
	A140	6,245,760	6/12/01	He et al.	514	234.8	11/24/98
	A141	6,248,129	6/19/01	Froix	623	1.42	10/23/98
	A142	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
	A143	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
	A144	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
	A145	6,258,371	7/10/01	Koulik et al.	424	422	4/3/98
	A146	6,262,034	7/17/01	Mathiowitz et al. /	514	44	11/25/97
	A147	6,270,788	8/7/01	Koulik et al.	424	423	10/4/99
	A148	6,277,449	8/21/01	Kolluri et al.	427	289	6/30/99
	A149	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
	A150	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
	A151	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
	A152	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99
	A153	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
	A154	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
	A155	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
	A156	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
رع	A157	6,344,035	2/5/02	Chudzik et al.	604	265	10/20/00

				,			
Q.	A158	6,346,110	2/12/02	Wu	606	108	1/3/01
	A159	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
	A160	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
	A161	6,387,379	5/14/02	Goldberg et al.	424	400	2/28/94
	A162	6,395,326	. 5/28/02	Castro et al.	427	2.24	5/31/00
	A163	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
	A164	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
	A165	6,482,834	11/19/02	Spada et al.	514	311	4/6/01
	A166	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
	A167	6,503,538	1/7/03	Chu et al.	424	497	8/30/00
:	A168	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
	A169	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
	A170	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
	A171	6,524,347	2/25/03	Myers et al.	2514	252.1	9/29/00
	A172	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
	A173	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
	A174	6,528,526	3/4/03	Myers et al.	214	311	9/29/00
	A175	6,530,950	3/11/03	Alvarado et al.	623	1.13	8/3/00
	A176	6,530,951	3/11/03	Bates et al.	623	1.45	10/23/97
	A177	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
	A178	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
	A179	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
	A180	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
	A181	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00
	A182	6,558,733	5/6/03	Hossainy et al.	427	2.24	10/26/00
	A183	6,565,659	5/20/03	Pacetti et al.	118	500	6/28/01
	A184	6,572,644	6/3/03	Moein	623	1.11	6/27/01
	A185	6,585,755	7/1/03	Jackson et al.	623	1.15	6/29/01
	A186	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29/00
41	A187	6,585,926	7/1/03	Mirzaee	264	400	8/31/00
Eek	A188	6,605,154	8/12/03	Villareal	118	500	5/31/01

1					_		
LG 3	A189	6,616,765	9/9/03	Hossaony et al.	623	1.45	1/10/02
F	A190	6,623,448	9/23/03	Slater	604	95.01	3/30/01
)	A191	6,625,486	9/23/03	Lundkvist et al.	604	21	4/11/01
	A192	6,645,135	11/11/03	Bhat _	600	3.	3/30/01
	A193	6,645,195	11/11/03	Bhat et al.	604	528	1/5/01
	A194	6,656,216	12/2/03	Hossainy et al.	623	1.13	6/29/01
	A195	6,656,506	12/2/03	Wu et al.	. 424	489	5/9/01
	A196	6,660,034	12/9/03	Mandrusov et al.	623	1.42	4/30/01
	A197	6,663,662	12/16/03	Pacetti et al.	623	1.13	12/28/00
	A198	6,663,880	12/16/03	Roorda et al.	424	423	11/30/01
	A199	6,666,880	12/23/03	Chiu et al.	623	1.11	6/19/01
	A200	6,673,154	1/6/04	Pacetti et al.	118	500	6/28/01
	A201	6,673,385	1/6/04	Ding et al.	427	2.28	6/28/01
	A202	6,689,099	2/10/04	Mirzaee	604	107	2/27/01
	A203	6,695,920	2/24/04	Pacetti et al.	118	500	6/27/01
	A204	6,706,013	3/16/04	* Bhat et al.	604	96.01	6/29/01
	A205	6,709,514	3/23/04	. Hossainy	118	52	12/28/01
	A206	6,712,845	3/30/04	Hossainy	623	1.42	4/24/01
	A207	6,713,119	3/30/04	Hossainy et al.	427	2.25	12/23/99
	A208	6,716,444	4/6/04	Castro et al.	424	422	9/28/00
	A209	6,723,120	4/20/04	· Yan	623	1.15	9/3/02
	A210	6,733,768	5/11/04	Hossainy et al.	424	426	6/25/02
	A211	6,740,040	5/25/04	Mandrusov et al.	600	439	1/30/01
	A212	6,743,462	6/1/04	Pacetti	427	2.24	5/31/01
	A213	6,749,626	6/15/04	Bhat et al.	623	1.1	11/17/00
	A214	6,753,071	6/22/04	Pacetti et al.	428	212	9/27/01
	A215	6,758,859	7/6/04	Dang et al.	623	1.15	10/30/00
4	A216	6,759,054	7/6/04	Chen et al.	424	423	12/28/00
X	A217	6,764,505	7/20/04	Hossainy et al.	623	1.15	4/12/01

Suc. and	L		· · · · · · · · · · · · · · · · · · ·	ION PUBLICATION DOCU		Subclass	Filing Date I
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Appropriate
JQ)	A218	2001/0007083	7/5/01	Roorda	623	1.15	12/21/00
7	A219	2001/0014717	8/16/01	Hossainy et al.	525	60	12/28/00
	A220	2001/0018469	8/30/01	Chen et al.	523	121	12/28/00
	A221	2001/0020011	9/6/01	Mathiowitz et al.	514	44	3/23/01
	A222	2001/0029351	10/11/01	Falotico et al.	604	103.02	5/7/01
	A223	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21/01
	A224	2001/0051608	12/13/01	Mathiowitz et al.	514	44	10/15/98
	A225	2002/0005206	1/17/02	Falotico et al.	128	898	5/7/01
	A226	2002/0007213	1/17/02	Falotico et al.	623	1.21	5/7/01
	A227	2002/0007214	1/17/02	Falotico	623	1.21	5/7/01
	A228	2002/0007215	1/17/02	Falotico et al.	623	1.21	5/7/01
	A229	2002/0009604	1/24/02	Zamora et al.	428	450	12/21/0
	A230	2002/0016625	2/7/02	Falotico et al.	623	1.13	5/7/01
	A231	2002/0032414	3/14/02	Ragheb et al.	604	265 .	5/7/01
	A232	2002/0032434	3/14/02	Chudzik et al.	604	890.1	11/21/0
•	A233	2002/0051730	5/2/02	Bodnar et al.	422	33	9/28/01
	A234	2002/0071822	6/13/02	Uhrich	424	78.37	7/27/01
	A235	2002/0077693	6/20/02	. Barclay et al.	623	1.13	12/19/0
	A236	2002/0082679	6/27/02	Sirhan et al.	623	1.15	11/1/01
	A237	2002/0087123	7/4/02	Hossainy et al.	604	198	1/2/01
	A238	2002/0091433	7/11/02	Ding et al.	623	1.2	12/17/0
	A239	2002/0094440	7/18/02	Lianos et al.	428	421	9/25/01
	A240	2002/0111590	8/15/02	Davila et al.	604	265	9/25/01
	A241	- 2002/0120326	8/29/02	Michal	623	1.15	12/22/0
	A242	2002/0123801	9/5/02	Pacetti et al.	623	1.46	12/28/0
	A243	2002/0142039	10/3/02	Claude	424	. 486	3/30/01
	A244	2002/0155212	10/24/02	Hossainy	427	2.25	4/24/01
	A245	2002/0165608	11/7/02	Llanos et al.	623	1.45	6/22/01
	A246	2002/0176849	11/28/02	Slepian	424	93.7	2/8/02
AV	A247	2002/0183581	12/5/02	Yoe et al.	600	3	5/31/01
USS.	A248	2002/0188037	12/12/02	Chudzik et al.	523	112	6/18/02

P				T		,	
588	A249	2002/0188277	12/12/02	Roorda et al.	604	523	5/18/01
4	A250	2003/0004141	1/2/03	Brown	514	152	3/8/02
	A251	2003/0028243	2/6/03	Bates et al.	623	1.15	8/14/02
	A252	2003/0028244	2/6/03	Bates et al.	623	1.15	8/14/02
	A253	2003/0031780	2/13/03	Chudzik et al.	427	2.1	10/10/02
	A254	2003/0032767	2/13/03	Tada et al.	528	310	2/5/01
	A255	2003/0036794	2/20/03	Ragheb et al.	623	1.15	8/19/02
	A256	2003/0039689	2/27/03	Chen et al.	424.	468	4/26/02
	A257	2003/0040712	2/27/03	Ray et al.	604	173	10/10/02
	A258	2003/0040790	2/27/03	Furst	623	1.11	7/31/02
	A259	2003/0059520	3/27/03	Chen et al.	427	2.1	9/27/01
	A260	2003/0060877	3/27/03	Falotico et al.	623	1.42	4/15/02
	A261	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30/02
	A262	2003/0072868	4/17/03	Harish et al.	427	2.24	11/25/02
	A263	2003/0073961	4/17/03	Нарр	604	274	9/28/01
-	A264	2003/0083646	5/1/03	Sirhan et al.	604	891.1	12/14/01
	A265	2003/0083739	5/1/03	Cafferata ·	623	1.42	9/24/02
	A266	2003/0097088	5/22/03	Pacetti	604	19	11/12/01
	A267	2003/0097173	5/22/03	Dutta	623	1.38	1/10/03
	A268	2003/0099712	5/29/03	Jayaraman .	424	486	11/26/01
	A269	2003/0105518	6/5/03	Dutta	623	1.38	1/10/03
	A270	2003/0113439	6/19/03	Pacetti et al.	427	2.24	11/18/02
	A271	2003/0150380	8/14/03	Yoe	118	423	2/19/03
	A272	2003/0157241	8/21/03	Hossainy et al.	427	2.24	3/5/03
	A273	2003/0158517	8/21/03	Kokish	604	103.01	2/11/03
	A274	2003/0190406	10/9/03	Hossainy et al.	427	2.25	4/10/03
	A275	2003/0207020	11/6/03	Villareal	427	2.24	4/22/03
	A276	2003/0211230	11/13/03	Pacetti et al.	427	2.24	4/7/03
	A277	2004/0018296	1/29/04	Castro et al.	427	2.25	6/23/03
	A278	2004/0029952	2/12/04	Chen et al.	514	449	8/1/03
	A279	2004/0047978	3/11/04	Hossainy et al.	427	2.1	8/12/03
	A280	2004/0047980	3/11/04	Pacetti et al.	427	2.25	9/8/03
1995	A281	2004/0052858	3/18/04	Wu et al.	424	490	9/15/03

				·			
	B20	EP 0 716 836	6/19/96	European			
Cha	B21	WO 96/40174	12/19/96	PCT			
(real	B22	WO 97/10011	3/20/97	PCT			
(i)	B23	EP 0 809 999	12/3/97	European			
(0)	B24	WO 97/45105	12/4/97	PCT			
R	B25	WO 97/46590	12/11/97	PCT	•		
(Z)	B26	WO 98/08463	3/5/98	PCT			
(e)	B27	EP 0 832 655	4/1/98	European			
(R)	B28	WO 98/17331	4/30/98	PCT			
7	B29	EP 0 850 651	7/1/98	European			
	B30	WO 98/32398	7/30/98	. PCT			
1	B31	WO 98/36784	8/27/98	PCT			
1	B32	EP 0 879 595	11/25/98	European			
1	B33	WO 99/01118	1/14/99	PCT			
	B34	EP 0 910 584	4/28/99	European			
	B35	EP 0 923 953	6/23/99	European			
1	B36	WO 99/38546	8/5/99	PCT			
·	B37	EP 0 953 320	11/3/99	European			
	B38	WO 99/63981	12/16/99	PCT			
	B39	EP 0 970 711	1/12/00	European			
	840	WO 00/02599	1/20/00	PCT			
1.	B41	EP 0 982 041	3/1/00	European		·	
	B42	WO 00/12147	3/9/00	PCT			
	B43	WO 00/18446	4/6/00	PCT			
	B44	EP 1 023 879	8/2/00	European			
,	B45	WO 00/64506	11/2/00	PCT			
	B46	WO 01/01890	1/11/01	PCT			
	B47	WO 01/15751	3/8/01	PCT ,			
	B48	WO 01/17577	3/15/01	PCT			
	B49	WO 01/45763	6/28/01	PCT			
	B50	WO 01/49338	7/12/01	PCT			
	B51	2001-190687	7/17/01	Japan (Abstract)		х	

										_
7	TQ)	A282	2004/0052859	3/18/04	Wu et al.	424	490	9/15	5/03	
F	P	A283	2004/0054104	3/18/04	Pacetti	526	242	9/5	/02	
		A284	2004/0060508	4/1/04	Pacetti et al.	118	264	9/12	2/03	
		A285	2004/0062853	4/1/04	Pacetti et al.	427	2.1	10/2	2/03	
Γ		A286	2004/0063805	4/1/04	Pacetti et al.	523	113	9/19	9/02	
		A287	2004/0071861	4/15/04	Mandrusov et al.	427	2.24	10/2	2/03	
		A288	2004/0072922	4/15/04	Hossainy et al.	523	113	10/9	9/02	
		A289	2004/0073298	4/15/04	Hossainy	623	1.46	10/8	3/03	12.1
		A290	2004/0086542	5/6/04	Hossainy et al.	424	423	12/1	6/02	
	1	A291	2004/0086550	5/6/04	Roorda et al.	424	448	10/2	4/03	
0	X	A292	2004/0096504	5/20/04	Michal	424	471	11/1	2/03	
1	1/0/5	A293	2004/0098117	5/20/04	Hossainy et al.	623	1.42	9/22	2/03	
E				FOREIGN PA	ATENT DOCUMENTS			·		
	Examiner	Ref. No.	Document	Date of	Country	Class	Subclass	Trans Yes	lation	
\vdash	Initial	177	Number	Publication 40/45/03	Caviat Haian				No	h
-		81	SU 872531	10/15/81	Soviet Union			- X		1/
Ŀ		B2	SU 876663	10/30/81	Soviet Union			_X_		/
L		В3	SU 905228	2/15/82	Soviet Union			X		7 Englar
L	<u> </u>	B4	SU 790725	2/9/83	Soviet Union			X		المهم ا
+		B5	SIL 1016314	5/7/83	Soviet Union			Х		
		B6	SU-811750	9/23/83	Soviet Union			X		
		87	SU 1293518	2/28/8 7	Soviet Union			Х		<i>y</i>
	720	B8	EP 0 301 856	2/1/89	European					
1	(Z)	В9	EP 0 396 429	11/7/90	European					
	(3)	B10	WO 91/12846	9/5/91	PCT	·				
7	Cel	B11	EP 0 514 406	11/25/92	European					
		B12	DE 42 24 401	1/27/94	Germany			-×		MA english
	Ella .	B13	WO 94/09760	5/11/94	PCT					
	\overline{a}	B14_	EP 0.604.022	6/29/94	European				-	Berne
7	els.	B15	EP 0 623 354	11/9/94	European		•] .
	ZW.	B16	WO 95/10989	4/27/95	PCT					
	(Ph)	B17	EP 0 665 023	8/2/95	European					
		B18_	WO 95/24929	9/21/95	PCT					het !
F		B19	EP 0 701 802	3/20/96	European					Record

)						_				
(The	B!	52	WO 01/51027	7/19/01	PCT						
1	B!	53	WO 01/74414	10/11/01	PCT						
	B!	54	WO 02/03890	1/17/02	PCT			ļ			
	B	55	EP 1 192 957	4/3/02	European						
	. В	56	WO 02/26162	4/4/02	PCT						
	В	57	WO 02/34311	5/2/02	PCT						
	B	58	WO 02/056790	7/25/02	PCT						
	В	59	WO 02/058753	8/1/02	PCT						
	В	60	WO 02/102283	12/27/02	PCT						
	В	61	WO 03/000308	1/3/03	PCT						
. 6	В	62	EP 1 273 314	1/8/03	European						
ľ	В	63	WO 03/022323	3/20/03	PCT						
	В	64	WO 03/028780	4/10/03	PCT						
1	В	65	WO 03/037223	5/8/03	PCT						
	В	66	WO 03/039612	5/15/03	PCT						
4	В	67	WO 03/080147	10/2/03	PCT				}		
R	В	68	WO 03/082368	10/9/03	PCT						
	— В	69	WO 04/000383	12/31/03	PCT	,		-	-		
(C)	B	70	WO 04/009145	1/29/04	PCT			·			
			OTHER DO	CUMENTS (Inc	luding Author, Title, Date, Pertinent Pa	ages, etc.)					
El	C	1	Anonymous, <i>Cardiolo</i> http://www.dialogweb	gists Draw - Up T .com/cqi/documer	he Dream Stent, Clinica 710:15 (Ju ht?req=1061848202959, printed 8/2	une 17, 19 25/03 (2 p	996), pages).				
ES) c	2	Anonymous, <i>Heparin</i>	-coated stents cut	complications by 30%, Clinica 732 ht?req=1061847871753, printed 8/2	:17 (Nov.	18, 1996	ŝ),			
Se	V c	3	Anonymous, <i>Rolling</i> (Abstract 434009), Ro		Loading Device for Therapeutic Ag	gent Deliv	very or C	oated S	tent		
SA) c		Anonymous, Stenting	continues to dom	inate cardiology, Clinica 720:22 (Set?reg=1061848017752, printed 8/2						
Pace	e c		Aoyagi et al., Preparation of cross-linked aliphatic polyester and application to thermo-responsive material, Journal of Controlled Release 32:87-96 (1994).								
	C		Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2): 252A (Abstract) (Feb. 1989).								
ta	С	7		ng of commercially	v available materials with a new he	parinizab	le materi	al, J. Bio	omed.		
	С	8		ore segment desig	n for drug delivery control of thermo	o-respon	sive poly	meric m	icelles,		

	\supseteq	<u> </u>		
(3		2	C9	Dev et al., Kinetics of Drug Delivery to the Arterial Wall Via Polyurethane-Coated Removable Nitinol Stent: Comparative Study of Two Drugs, Catheterization and Cardiovascular Diagnosis 34:272-278 (1995).
	7			Dichek et al., Seeding of Intravascular Stents with Genetically Engineered Endothelial Cells, Circ. 80(5):1347-1353 (Nov. 1989).
			C11	Eigler et al., Local Arterial Wall Drug Delivery from a Polymer Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin, JACC, 4A (701-1), Abstract (Feb. 1994).
			C12	Helmus, Overview of Biomedical Materials, MRS Bulletin, pp. 33-38 (Sept. 1991).
			C13 _.	Herdeg et al., Antiproliferative Stent Coatings: Taxol and Related Compounds, Semin. Intervent. Cardiol. 3:197-199 (1998).
			C14	Huang et al., Biodegradable Polymers Derived from Aminoacids, Macromol. Symp. 144, 7-32 (1999).
			C15	Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).
·		٠	C16	Kataoka et al., Block copolymer micelles as vehicles for drug delivery, Journal of Controlled Release 24:119-132 (1993).
•			C17	Katsarava et al., Amino Acid-Based Bioanalogous Polymers. Synthesis and Study of Regular Poly(ester amide)s Based on Bis(α-amino acid)α,ω-Alkylene Diesters, and Aliphatic Dicarboxylic Acids, Journal of Polymer Science, Part A: Polymer Chemistry, 37(4), 391-407 (1999).
			C18	Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
				Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
•			C20	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).
Ŀ			C21	Matsumaru et al., <i>Embolic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
			C22	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
			C23	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
			C24	Nordrehaug et al., A novel biocompatible coating applied to coronary stents, European Heart Journal 14, p 321 (P1694), Abstr. Suppl. (1993).
			C25	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998)
			C26	Ozaki et al., New Stent Technologies, Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
			C27	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).
	V		Ĉ28	Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).
6	*		C29	Saotome, et al., Novel Enzymatically Degradable Polymers Comprising α-Amino Acid, 1,2-Ethanediol, and Adipic Acid, Chemistry Letters, pp. 21-24, (1991).
1	a de	\supset	C30	Shigeno, Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor, Chemical Abstract 125:212307 (1996).
4.8		1	C31	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).
Z	9	,	C32	Wilensky et al., Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries, Trends Cardiovasc. Med. 3(5):163-170 (1993).

C33 Yokoyama et al., Chapolymeric micelles and 50:79-92 (1998).	racterization of physical entrapment and chemical conjugation of adriamycin in d their design for in vivo delivery to a solid tumor, Journal of Controlled Release
EXAMINER 2	DATE CONSIDERED ONON
EXAMINER: Initial if references considered, whether or	not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.